Belgian biopharmaceutical company Cardio3 Biosciences, which is backed by a consortium of venture capital firms, has announced that it is considering listing new shares in an IPO.
The company, which raised €19m last month from existing investors in the form of €7m in fresh equity and €12m as a conversion of convertible loans, hopes to raise new funds through an IPO on NYSE...
Seventure, Holtzbrinck and other investors have backed a $10m series-D for Payleven
GP and members of Countryside's management team received £174m from the flotation
Round follows first £2.5m injection by VC into drone inspection specialist
Both investors will control a minority stake in the business alongside the CEO and majority owner